Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
about
A novel small molecule inhibitor of hepatitis C virus entryMechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavirAntiviral treatment of chronic hepatitis B virus (HBV) infectionsEntecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients.New approaches for quantitating the inhibition of HIV-1 replication by antiviral drugs in vitro and in vivo.Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus.Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs.Infection-related cancers in sub-saharan Africa: a paradigm for cancer prevention and control.Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase.HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: structural insights into HBV-RT inhibition by entecavir.
P2860
Q28475468-B25F9788-1123-4927-B5A1-951E5DEB01FBQ28748931-2F3F51FF-7928-4C8B-A152-E924FFB4E63DQ34223779-5BC868B0-AF9E-4DFD-95CF-D9FC6CB817A3Q37291331-C8458CB3-7755-4854-8676-5FB05F4454B9Q37617931-5A2EFB7E-36E6-490D-A8FD-116C30AFCF2AQ37885453-13A57ED6-647E-4088-8A3F-502395126E9FQ38067130-E88A56A2-8B25-4EEE-988D-B80C68B8EC17Q38866854-DB4A1CE3-3F50-467E-A77E-D93EDF3C62A4Q39178072-3CE45083-5473-4068-B74B-29125188EC24Q40749461-8E3DE15C-796F-49DE-9E7D-EDD32789C27EQ41503130-875270BB-BB25-4CCA-BDBA-FD3BCBC5BD15Q47548606-DBACB2E5-2B34-40D1-93DB-C26FFF6DA20C
P2860
Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Entecavir exhibits inhibitory ...... ns of reduced viral challenge.
@en
type
label
Entecavir exhibits inhibitory ...... ns of reduced viral challenge.
@en
prefLabel
Entecavir exhibits inhibitory ...... ns of reduced viral challenge.
@en
P2093
P2860
P356
P1476
Entecavir exhibits inhibitory ...... ns of reduced viral challenge.
@en
P2093
Beata Nowicka-Sans
Brian Terry
Chunfu Wang
Daniel Tenney
Helen Higley
Ira Dicker
Mark Krystal
Neil Parkin
Pin-Fang Lin
P2860
P304
P356
10.1128/AAC.01313-07
P407
P577
2008-03-03T00:00:00Z